Skip to main content

Table 4 Construct validity of clinical tools for assessing localized scleroderma with Skindex-29 subscales

From: Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study

 

Skindex-29: emotions

Skindex-29: symptoms

Skindex-29: functioning

rs

p

rs

p

rs

p

mLoSSI

−0.05

0.76

−0.20

0.21

0.09

0.6

PhysGA-A

−0.13

0.44

0.04

0.81

0.07

0.65

PtGA-S

0.16

0.33

0.27

0.33

0.24

0.14

LoSDI

0.12

0.45

0.02

0.93

0.15

0.36

PhysGA-D

0.32

0.04

0.44

< 0.01

0.37

0.02

PtGA-D

0.4

< 0.01

0.48

< 0.01

0.38

< 0.01

  1. mLoSSI modified Localized Scleroderma Skin Severity Index, PhysGA-A physician global assessment of disease activity, PtGA-S patient global assessment of disease severity, LoSDI Localized Scleroderma Damage Index, PhysGA-D physician global assessment of disease damage, PtGA-D patient global assessment of disease damage, rs Spearman’s rank correlation coefficient, p p-value
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us